Skip to main content

Table 1 Characteristics of the included studies for the meta analyses

From: Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Study

Year

Country

N (1)

N (2)

N (3)

Percent of TP53 co-mutation

Methods of gene detection

Sample

Clinical stage

Pathological type

Detected exons of TP53

Study type

CLCGP

2013

USA

1255

80

27/53

33.75%

Sanger Sequencing

tissue

III, IV

NSCLC

2–11

Retro

Molina-Vila

2014

Europe

193

193

50/143

25.91%

HRM technique

tissue

IIIB, IV

NSCLC

5–8

Retro

Bria E

2015

Italy

18

18

7/11

38.89%

NGS or Sanger sequencing

tissue

IIIB, IV, recurrent

ADC

2–11

Retro

Canale M

2017

Italy

123

123

37/86

30.08%

Direct Sequencing

tissue

advanced

ADC (98.5%)

5–8

Retro

Labbé C

2017

Canada

105

60

24/36

40%

NGS or Sanger sequencing

tissue

advanced

ADC (96.19%)

5–10/2–11

Retro

Vander Laan

2017

USA

171

20

10/10

50%

Sanger sequencing

tissue

IV, recurrent

ADC

5–8

Retro

Aisner

2018

USA

904

35

21/14

60%

NGS

tissue

IV, recurrent

NSCLC

2–11

Pro

Tsui DWY

2018

UK

50

30

12/18

40%

TAm-Seq

plasma

IV

NSCLC

5–8

Pro

HelenaA.Yu

2018

USA

200

200

119/81

59.5%

NGS

tissue

IV

ADC

2–11

Retro

Youjin Kim

2018

Korea

200

75

43/32

57.33%

NGS

tissue

advanced

NSCLC

2–11

Retro

Youjin Kim

2018

Korea

–

82

50/32

60.98%

NGS

tissue

advanced

NSCLC

2–11

Retro

Rachiglio AM

2019

China

133

133

23/110

17.29%

NGS

tissue

advanced, metastatic

NSCLC

2–11

Retro

Kron A

2018

Germany

216

93

22/71

26.19%

NGS

tissue

IIIB, IV

ADC

2–11

Retro

Kron A

2018

Germany

–

33

11/22

33.33%

NGS

tissue

IIIB, IV

ADC

2–11

Retro

Yu Y

2018

China

52

35

21/14

60%

Illumina HiSeq400 platform

tissue

III, IV

ADC

2–11

Retro

Christopoulos P

2019

Germany

102

68

21/47

30.88%

NGS

tissue

IV

ADC

2–11

Mixed

Song P

2019

China

64

64

15/49

23.44%

NGS

tissue

IIIB, IV

ADC (98.4%)

2–11

Retro

Study

Targeted drugs

Treatment line

Outcome

Analysis method

HR estimation

CLCGP

EGFR-TKIs

All lines

OS

Multivariate

Calculated from raw data

Molina-Vila

EGFR-TKIs

All lines

OS

Multivariate

Reported

Bria E

EGFR-TKIs

First line

PFS, OS

Univariate

Reported

Canale M

EGFR-TKIs

First line

PFS, OS

Univariate

Reported

Labbé C

EGFR-TKIs

First line

PFS, OS

Multivariate

Reported

Vander Laan

EGFR-TKIs

All lines

PFS, OS

Multivariate

SC

Aisner

EGFR-TKIs

All lines

OS

Not reported

SC

Tsui DWY

EGFR-TKIs

First line

PFS, OS

Not reported

Reported

HelenaA.Yu

EGFR-TKIs

All lines

PFS, OS

Not reported

Calculated from raw data

Youjin Kim

EGFR-TKIsa

First line

PFS, OS

Multivariate

Reported

Youjin Kim

EGFR-TKIsb

second line

PFS, OS

Multivariate

Reported

Rachiglio AM

EGFR-TKIs

First line

PFS, OS

Multivariate

Reported

Kron A

ALK-TKIsc

All lines

PFS, OS

Multivariate

Reported

Kron A

ALK-TKIsd

All lines

PFS, OS

Multivariate

Reported

Yu Y

ALK-TKIs

First line

PFS

Not reported

Reported

Christopoulos P

ALK-TKIs

All lines

PFS

Not reported

Calculated from raw data

Song P

ALK-TKIs

All lines

PFS

univariate

Reported

  1. N (1), number of patients involved in each study; N (2), number of patients with concurrent mutations of both TP53 and targetable EGFR or ALK mutations and received targeted therapy; N3, number of patients with/without concurrent TP53 mutations; a, first and second generation EGFR-TKIs---gefitinib, erlotinib, afatinib; b, third generation EGFR-TKIs---osimertinib, olmutinib; c, first generation ALK-TKIs--- crizotinib; d, ceritinib, alectinib, second generation ALK-TKIs---brigatinib
  2. Abbreviations: NGS Next-generation sequencing, TAm-Seq Tagged-amplicon deep sequencing, Retro Retrospective study, Pro Prospective study, EGFR Epidermal growth factor receptor, ALK Anaplastic lymphoma kinase, TKI Tyrosine kinase inhibitor